Sjogrens Syndrome Market: By Drug By Type By End-User and Geography

Sjogrens Syndrome Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug (Pilocarpine, Cyclosporine, NSAIDS, Hydroxychlroquine) By Type (Primary Sjogrens Syndrome, Secondary Sjogrens Syndrome) By End-User (Hospitals, Clinics, Pharmacies, Online Pharmacies) and Region

Sjogren’s Syndrome Market size was valued at US$ 235.6 billion in 2023 and is poised to grow at a CAGR of 3.6% from 2024-2030. Sjogren's syndrome is an autoimmune condition that develops when the body’s immune system attacks the gland that produces moisture in the mouth, eyes, and other body parts resulting in dryness of the eyes and mouth due to inflammation and resultant pathology of the lacrimal and salivary glands. Up to 50% of those who are affected also experience extra-glandular involvement in other organs, including the joints, skin, lungs, GI tract, neurological system, and kidneys.

According to WHO, approximately 1% of the U.S. population is affected by Sjogren’s with 9 out of 10 patients being women. The treatment regimen generally includes local therapies like pilocarpine, and cevimeline and, systemic therapies like corticosteroids, hydroxychloroquine, and immunosuppressants. The increase in incidence of Sjogren’s syndrome, increased awareness of preventive attention and increased income among the population is currently driving the market.

The recent studies focussing on alternative strategies in molecular technology have produced a wide range of novel putative blood, salivary, and histologic biomarkers, increasing the opportunities for market development. The development of a robust drug pipeline during COVID-19 has presented huge opportunities for the development of several NSAIDs and hydroxychloroquine and is expected to have a significant impact on the Sjogren’s syndrome market. For instance, in January 2023, Horizon announced that Dazodalibep had achieved approval in 2nd phase and is currently undergoing 3rd phase. Based on key molecule type, the biologics segment is dominating the market owing to the extensive use of B-cell targeted therapies, therapies targeting various cytokines, chemokines, and Toll-like receptors.  

However according to research conducted currently, no permanent cure is available, treatments only treat the symptoms or are viewed as ineffective by many patients. Moreover, tight government regulations, expensive treatment costs, and Sjogren's disease consequences including acute dehydration, considerable weight loss, and inflammation, slows down the market's expansion. However, a rise in awareness of preventive attention, an increase in disposable income among the population, developed infrastructure, and increased pharmaceutical and biotechnology industries have a significant positive effect on the market and are expected to burgeon in the forecast period.

Sjogren’s Syndrome Market Key Developments:

  • In February 2022, Dompe announced the first patient enrolment in the Phase 3 trial of cenegermin in patients with severe Sjogren’s-related dry eye disease.
  • In March 2019, Wize Pharma, Inc., a clinical-stage biopharmaceutical company focused on ophthalmic disorders announced LO2A Licensor, Resdevco, was granted market approval for the treatment of Sjögren's Syndrome in Hungary

Sjogrens Syndrome Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.6%

Largest Market

North America

Fastest Growing Market

North America

Sjogrens Syndrome Market Dynamics

Growing incidence of sjogrens syndrome coupled with rising awareness the sjogrens syndrome are expected to drive the growth of sjogrens syndrome market. Furthermore, increase in patient pool with rheumatoid arthritis and lupus, environmental pollution, growing demand for the advanced treatments and therapies are expected to boost the growth of the sjogrens syndrome market. However, lack of awareness is a major drawback sjogrens syndrome market.

Sjogrens Syndrome Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 235.6 billion

Market CAGR

3.6%

By Drug

  • Pilocarpine
  • Cyclosporine
  • NSAIDS
  • Hydroxychloroquine

By Type

  • Primary Sjogrens Syndrome
  • Secondary Sjogrens Syndrome

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and africa

Key Features of the Report

  • The sjogren's syndrome market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The global sjogrens syndrome market size was valued at US$ 235.6 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024-2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The sjogrens syndrome market key players are Allergan Inc. (Ireland) Auven Therapeutics (U.S.) Novartis AG (Switzerland) Santen Pharmaceutical Co. Ltd. (Japan) Otsuka Pharmaceutical Co., Ltd. (Japan) Argentis Pharmaceuticals, LLC. (UK)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Sjogrens Syndrome Market Introduction 
2.1.Global Sjogrens Syndrome Market  - Taxonomy
2.2.Global Sjogrens Syndrome Market  - Definitions
2.2.1. By Drug 
2.2.2. By Type
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Sjogrens Syndrome Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Sjogrens Syndrome Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Sjogrens Syndrome Market  By Drug , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Pilocarpine
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Cyclosporine
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. NSAIDS
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Hydroxychloroquine
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Sjogrens Syndrome Market  By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Primary Sjogrens Syndrome
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Secondary Sjogrens Syndrome
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Sjogrens Syndrome Market  By  Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Sjogrens Syndrome Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Sjogrens Syndrome Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Pilocarpine
9.1.2.Cyclosporine
9.1.3.NSAIDS
9.1.4.Hydroxychloroquine
9.2.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Primary Sjogrens Syndrome
9.2.2.Secondary Sjogrens Syndrome
9.3.   Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Sjogrens Syndrome Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Pilocarpine
10.1.2.Cyclosporine
10.1.3.NSAIDS
10.1.4.Hydroxychloroquine
10.2.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Primary Sjogrens Syndrome
10.2.2.Secondary Sjogrens Syndrome
10.3.   Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Pilocarpine
11.1.2.Cyclosporine
11.1.3.NSAIDS
11.1.4.Hydroxychloroquine
11.2.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Primary Sjogrens Syndrome
11.2.2.Secondary Sjogrens Syndrome
11.3.   Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Pilocarpine
12.1.2.Cyclosporine
12.1.3.NSAIDS
12.1.4.Hydroxychloroquine
12.2.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Primary Sjogrens Syndrome
12.2.2.Secondary Sjogrens Syndrome
12.3.   Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Sjogrens Syndrome Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Pilocarpine
13.1.2.Cyclosporine
13.1.3.NSAIDS
13.1.4.Hydroxychloroquine
13.2.  Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Primary Sjogrens Syndrome
13.2.2.Secondary Sjogrens Syndrome
13.3.   Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Allergan Inc. (Ireland)
14.2.2.Auven Therapeutics (U.S.)
14.2.3.Novartis AG (Switzerland)
14.2.4.Santen Pharmaceutical Co. Ltd. (Japan)
14.2.5.Otsuka Pharmaceutical Co., Ltd. (Japan)
14.2.6.Argentis Pharmaceuticals, LLC. (UK)
14.2.7.Nicox S.A. (France)
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Allergan Inc. (Ireland)
  • Auven Therapeutics (U.S.)
  • Novartis AG (Switzerland)
  • Santen Pharmaceutical Co. Ltd. (Japan)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Argentis Pharmaceuticals, LLC. (UK)
  • Nicox S.A. (France)

Related Industry Reports